HC Wainwright & Co. Downgrades IGM Biosciences to Neutral, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has downgraded IGM Biosciences (NASDAQ:IGMS) from Buy to Neutral and reduced the price target from $11 to $7.
December 07, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
IGM Biosciences was downgraded by HC Wainwright & Co. from Buy to Neutral, with a price target decrease from $11 to $7.
Downgrades by analysts, especially with a significant price target reduction, typically lead to negative investor sentiment and can result in a short-term decline in the stock price. The direct mention of IGM Biosciences and the specific details of the downgrade suggest a high relevance and importance to the company's stock. The confidence level is high due to the clear and direct impact analyst ratings have on stock performance, particularly in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100